Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Inclusion Criteria: * Healthy male subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>=50 years * BMI \>=18.5 and \<=29.9 kg/m2 * Able to communicate well with the investigator and to comply with study requirements * Laboratory values within a clinically defined reference range Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial) * Use of any drugs, which might influence the results of the trial, (\< 10 days prior to administration or during the trial) * Participation in another trial with an investigational drug (\< 3 months prior to administration (at least 10 times the relevant elimination half-life) or during trial) * Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life) * Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood donation or loss \> 400 mL (\< 1 month prior to administration or during the trial) * Excessive physical activities (\< 5 days prior to administration or during the trial) * Any ECG value outside of the reference range of clinical relevance including, but not limited to QTcB \> 480 ms or QRS interval \> 110 ms * History of any familial bleeding disorder * Inability to comply with dietary regimen of study centre * Inability to comply with investigator's instructions